Get the Stockscreener App
1.82
13.75%
0.22
Pre-market:
1.89
0.07
+3.85%
Biorestorative Therapies Inc stock is traded at $1.82, with a volume of 2.50M.
It is up +13.75% in the last 24 hours and down -21.55% over the past month.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
See More
Previous Close:
$1.60
Open:
$1.64
24h Volume:
2.50M
Relative Volume:
7.40
Market Cap:
$12.59M
Revenue:
$149.50K
Net Income/Loss:
$-6.96M
P/E Ratio:
-1.3382
EPS:
-1.36
Net Cash Flow:
$-6.37M
1W Performance:
-8.77%
1M Performance:
-21.55%
6M Performance:
+7.05%
1Y Performance:
+32.85%
1-Day Range:
$1.5701
$1.91
1-Week Range:
$1.57
$2.3798
52-Week Range:
$1.03
$2.55
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Compare BRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
1.82 | 12.59M | 149.50K | -6.96M | -6.37M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Biorestorative Therapies Inc Stock (BRTX) Latest News
BioRestorative to Provide a Positive FDA Update on Clinical Pipeline - The Manila Times
FDA Green Light? BioRestorative Teases Major Clinical Breakthrough for Stem Cell Therapies - StockTitan
Comparing Quipt Home Medical (NASDAQ:QIPT) & BioRestorative Therapies (NASDAQ:BRTX) - Defense World
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program - GlobeNewswire
Can This FDA-Fast-Tracked Therapy Finally Solve Chronic Back Pain? Phase 2 Data Shows Promise - StockTitan
Contrasting Quipt Home Medical (NASDAQ:QIPT) and BioRestorative Therapies (NASDAQ:BRTX) - Defense World
Roth Capital Has Pessimistic Outlook of BRTX FY2028 Earnings - Defense World
BioRestorative Therapies Presents at Orthopaedic Research Society Annual MeetingBioRestorative Therapies, Inc. recently made an announcement through a press release on February 10, 2025, regarding its participation in the Orthopaedic Research Societ - Defense World
BioRestorative Therapies Issues Regulation FD Disclosure - TipRanks
BRTX-100 Front and Center at ORS 2025 - GlobeNewswire
Game-Changing Clinical Data: BRTX-100 Achieves 73% Pain Relief in Chronic Back Pain Trial - StockTitan
BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Shift From Loss To Profit - Yahoo Finance
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Down 0.9%Here's Why - MarketBeat
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting - ACCESS Newswire
With BioRestorative Therapies Up 18%, Insider Buyers Count Their Returns - Simply Wall St
BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Up 0.7%Here's Why - MarketBeat
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Up 0.7% – Here’s What Happened - Defense World
BioRestorative Therapies, Inc. announced that it has received $1 million in funding - Marketscreener.com
Pleasing Signs As A Number Of Insiders Buy BioRestorative Therapies Stock - Yahoo Finance
BioRestorative Therapies (OTCMKTS:BRTX) Share Price Passes Above Fifty Day Moving Average – Here’s What Happened - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Hits New 12-Month HighTime to Buy? - MarketBeat
BioRestorative Therapies Announces Notice of Allowance of - GlobeNewswire
BioRestorative Therapies Secures Key European Patent for Revolutionary Obesity Treatment Technology - StockTitan
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial - Nasdaq
BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain TrialEli Lilly (NYSE:LLY), BioRestorative Therapies (NASDAQ:BRTX) - Benzinga
Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market - Nasdaq
BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World
Analyzing American Caresource (OTCMKTS:GNOW) & BioRestorative Therapies (NASDAQ:BRTX) - Defense World
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q3 2024 Earnings Call Transcript - Insider Monkey
BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BioRestorative Therapies earnings beat by $0.31, revenue fell short of estimates - Investing.com Canada
BioRestorative Therapies Q3 2024 Financial Update - TipRanks
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function - Benzinga
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data - OrthoSpineNews
BioRestorative's BRTX-100 Shows 100% Success Rate in Early Back Pain Trial Data | BRTX Stock News - StockTitan
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
BioRestorative Therapies Enters at-the-Market Offering Agreement with Rodman & Renshaw LLC - Defense World
Roth Capital Issues Optimistic Outlook for BRTX Earnings - Defense World
BioRestorative Therapies to Announce Phase 2 Trial Data - TipRanks
Research Analysts Offer Predictions for BRTX Q1 Earnings - Defense World
BioRestorative Therapies inks new equity deal - Investing.com
BioRestorative Therapies inks new equity deal By Investing.com - Investing.com UK
BRTXBioRestorative Therapies, Inc. Latest Stock News & Market Updates - StockTitan
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium - The Manila Times
BioRestorative to Present Expanded BRTX-100 Phase 2 Trial Data for Chronic Back Pain Treatment | BRTX Stock News - StockTitan
Broadrick Dale reduces stake in BioRestorative Therapies, Inc. with $1,756 sale - Investing.com
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - GlobeNewswire
BioRestorative Therapies (OTCMKTS:BRTXQ) Reaches New 12-Month HighShould You Buy? - MarketBeat
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program - GlobeNewswire
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):